Litigation Details for Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Docket	1:21-cv-00283	Date Filed	2021-02-24
Court	District Court, D. Delaware	Date Terminated	2022-01-19
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,610,510; 10,610,511; 10,829,465
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-02-24				External link to document

Vanda Pharmaceuticals v. MSN (1:21-cv-00283): Litigation Summary, Claims, Timeline, and Patent-Validity/Exclusivity Exposure

Last updated: July 17, 2026

Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc., No. 1:21-cv-00283, is a Hatch-Waxman patent litigation in the US addressing MSN’s generic entry plan for Vanda’s branded product and Vanda’s asserted Orange Book-listed US patents. The case posture and practical exposure hinge on (1) which patents Vanda listed and asserted, (2) whether MSN filed a Paragraph IV certification, (3) the court’s claim construction and any dismissal/summary-judgment rulings, and (4) settlement versus trial outcomes that determine launch timing and design-around paths.

What patents are at issue in Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. (1:21-cv-00283)?

Answer: The patents at issue are the Orange Book US patents that Vanda asserted against MSN’s ANDA-based generic filing. The exact patent list is determinative of scope because Vanda’s asserted claims typically cover one or more of: the drug substance (composition), specific formulations, and/or method-of-use.

How to identify the asserted patent set in this docket

In Hatch-Waxman suits, the complaint lists the Orange Book patents corresponding to the ANDA and identifies each asserted US patent number and infringement theory. The asserted set also maps to the ANDA’s certification type:

• Paragraph IV (not infringed or invalid) drives litigation for those patents.
• Non-Paragraph IV certifications do not typically generate patent-infringement litigation on that patent.

What claim types usually dominate Vanda-style estates

For Vanda products, the estate often includes:

• Formulation patents tied to pharmacokinetics and/or dosing performance.
• Method-of-use patents tied to defined treatment paradigms.
• Composition patents that remain barriers even if the formulation is redesigned.

What is the litigation timeline for Vanda v. MSN (1:21-cv-00283)?

Answer: This case was filed in 2021 in the US district court as a Hatch-Waxman patent action. The litigation timeline typically proceeds through pleadings, claim construction, dispositive motions, and then either settlement or trial.

Filing and procedural milestones (what matters commercially)

For launch timing and damages exposure, the key dates are:

1. Complaint filing and service (triggers 30-month stay if Paragraph IV is timely and the NDA/ANDA requirements align).
2. First substantive case management order and scheduling for claim construction.
3. Claim construction order (sets infringement/validity posture).
4. Summary judgment or dismissal (narrows claims/patents).
5. Settlement agreement date (if any) and the agreed effective launch date.
6. Post-judgment appeals (if an adverse outcome is appealed).

Why the “30-month stay” question controls outcomes

Even if a patent is later found invalid or not infringed, the 30-month stay can delay FDA approval and commercial launch while the litigation is pending. Conversely, early claim narrowing can create a path for an eventual at-risk launch if FDA approval is obtained.

When does exclusivity end for the branded Vanda product that MSN challenged?

Answer: Exclusivity ending depends on the drug’s listed exclusivity in the Orange Book (drug product exclusivity, pediatric exclusivity, and any data exclusivity tied to the NDA/BLA history) and on patent expiration or settlement carve-outs. The Orange Book release and listed patents govern.

Patent expiration versus exclusivity

In practical filings, the “earliest date” for generic entry is the maximum of:

• Patent expiration dates (or license/settlement “allowed” dates).
• Exclusivity end date (where applicable).
• Any stay-triggered delay caused by Paragraph IV litigation and FDA review timing.

Which companies are challenging and defending patents in this case?

Answer: Vanda Pharmaceuticals Inc. is the plaintiff asserting infringement of listed patents. MSN Pharmaceuticals Inc. is the ANDA filer and defendant challenging those patents through the Paragraph IV framework, typically via invalidity and non-infringement defenses.

Roles in Hatch-Waxman

• Plaintiff: asserts Orange Book patents and infringement.
• Defendant: certifies the patents are invalid, unenforceable, and/or not infringed.
• FDA: not a direct party, but regulates ANDA approval timing.

How strong is Vanda’s patent estate in this dispute?

Answer: Strength is driven by (1) whether Vanda’s asserted claims are narrow and specific to formulation or dosage performance and (2) the likelihood that construction will read on MSN’s ANDA product. If the asserted patents are formulation or method-of-use claims that require specific drug release, absorption, or patient-use conditions, construction can be outcome-determinative.

Common strength/weakness signals in district-court outcomes

• Claim construction alignment: if the generic product’s design meets construed claim elements.
• Obviousness or written description vulnerability: formulation estates often face the toughest validity challenges.
• Prior art fit: if prior art teaches the same formulation/manufacturing method or the same dosing regimen.

What formulations and dosing technologies are covered by the asserted claims?

Answer: The asserted claims typically cover either a defined formulation approach (excipients, manufacturing method, release profile) or a method-of-use dosing regimen. The specific formulation elements depend on the asserted patent claims listed in the complaint.

Why formulation details decide infringement

In ANDA litigation, the generic product is compared to the patented formulation elements claim-by-claim. A small change in:

• excipient identity,
• release characteristics,
• manufacturing process steps, can break literal infringement, leaving only doctrine-of-equivalents theories.

What generic entry risks exist for MSN in Vanda v. MSN?

Answer: The generic entry risks include:

• A remaining injunction risk if the court finds infringement and denies invalidity arguments.
• An at-risk launch risk if the case settles on terms that allow FDA approval while some patent issues remain.
• A design-around risk if construction narrows claims but does not invalidate them.

How settlements typically allocate entry

In Hatch-Waxman, settlement terms often include:

• a launch date tied to patent expiration or a carve-out date,
• licensing payments,
• covenant not to sue on specific patents or for specific dosage forms.

How does Vanda v. MSN compare with other Vanda generic challenges?

Answer: Case-to-case comparisons depend on whether Vanda is enforcing composition/formulation patents or method-of-use patents, and whether the generic’s defenses focus on invalidity (anticipation/obviousness) or on non-infringement.

Typical patterns for Vanda portfolios

• Formulation-heavy cases tend to turn on claim construction and lab/technical comparators.
• Method-of-use cases turn on whether the generic product label triggers the patented “use” conditions, and on statutory and label-based infringement theories.

What is the Orange Book status of the patents in dispute?

Answer: The Orange Book status determines what is enforceable under Hatch-Waxman. The asserted patents are the ones listed for the branded drug and tied to the NDA and dosage form at issue.

What the Orange Book listing implies procedurally

• If a patent is Orange Book-listed and tied to the NDA, it can support an infringement suit.
• If the patent is delisted or expires during the case, it can moot or narrow the dispute.

What Paragraph IV and FDA pathway issues matter here?

Answer: The key issue is whether MSN filed a Paragraph IV certification for the asserted patents, triggering litigation and potentially a 30-month stay.

ANDA approval timing versus court timing

Even with an approved ANDA, market entry can still be blocked by:

• injunctive relief,
• settlement terms,
• unresolved appellate stays.

How does claim construction affect validity and infringement outcomes?

Answer: Claim construction can effectively decide the case by:

• enabling non-infringement if the generic product does not meet construed elements,
• enabling invalidity if prior art more cleanly reads on the narrowed construction,
• or forcing narrow interpretations that preserve infringement but weaken validity.

What to watch in district-court orders

• Construction of key terms in formulation claims (release rate, particle size, excipient constraints).
• Construction of dosing regimen terms in method-of-use claims.
• Whether the court adopts a narrow construction that reduces doctrine-of-equivalents overlap.

What patent litigation outcomes change launch timing?

Answer: The critical decision points are:

• Final finding on infringement (enables injunction risk).
• Invalidity rulings (removes barriers).
• Settlement terms (often replace litigation risk with a scheduled entry date).

Scenario map: where business outcomes land

• Vanda win on at least one asserted patent: generic launch delayed and may be enjoined.
• MSN win on all asserted patents: FDA approval can translate into earlier launch if no appeal or stay exists.
• Settlement: commercial launch date shifts to the settlement schedule.

Key Takeaways

• The case is a Hatch-Waxman patent dispute tied to Orange Book-listed patents and MSN’s ANDA entry plan.
• Business risk and launch timing depend on which patents were asserted, how the court construed key claim terms, and whether the matter resolved via dismissal/summary judgment or settlement.
• Formulation or method-of-use claim structures typically drive outcome sensitivity to claim construction and product/label comparisons.

FAQs

1) Does Vanda v. MSN involve a 30-month stay under Hatch-Waxman?
The stay is triggered by timely Paragraph IV litigation tied to an ANDA. The operational effect is delayed FDA approval or delayed effective entry depending on case timing and any court orders.

2) Are method-of-use patents enforceable based on ANDA labeling rather than product composition?
Yes, when the patented “use” is tied to treatment instructions, courts often evaluate infringement based on how the ANDA label would direct physicians and patients.

3) What claim terms typically decide formulation ANDA infringement cases?
Terms tied to excipient selection, release profile metrics, manufacturing constraints, and any defined physical attributes that create a measurable difference.

4) What invalidity defenses are most common in these disputes?
Anticipation and obviousness under 35 USC 102/103, plus written description and enablement challenges under 35 USC 112 depending on the claims’ characteristics.

5) What usually controls settlement and entry timing after a claim construction ruling?
The narrowed claim scope and perceived likelihood of surviving dispositive motions, which drive settlement economics and the agreed launch date.

References (APA)

1. US District Court docket, Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc., No. 1:21-cv-00283.